Neurodevelopmental outcomes in infants receiving opioid-replacement

Infants with Neonatal Opioid Withdrawal Syndrome (NOWS) are often treated with prolonged opioid-replacement pharmacotherapy. Whether opioid exposure in-utero or significant opioid exposure used to treat withdrawal symptoms impacts neurodevelopmental outcomes is unknown. Our aim is to evaluate neurodevelopmental outcomes at ages 24-72 months in infants who received opioids-replacement pharmacotherapy (treated NOWS infants), compared to those who did not receive pharmacotherapy (untreated NOWS). Our secondary aim is to evaluate maternal demographic and clinical characteristics as potential risk modifiers associated with adverse neurodevelopmental outcomes.

0